Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

January 31, 2006

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

oblimersen sodium

DRUG

docetaxel

Trial Locations (16)

1000

Institut Jules Bordet, Brussels

1200

Cliniques Universitaires Saint-Luc, Brussels

2100

Rigshospitalet - Copenhagen University Hospital, Copenhagen

2700

Hospital Desterro, Lisbon

38043

CHU de Grenoble - Hopital de la Tronche, Grenoble

70300

Assaf Harofeh Medical Center, Ẕerifin

A-1100

Kaiser Franz Josef Hospital, Vienna

B-9300

Onze Lieve Vrouw Ziekenhuis Aalst, Aalst

B-9000

Universitair Ziekenhuis Gent, Ghent

B-3000

U.Z. Gasthuisberg, Leuven

00152

Ospedale S. Camillo-Forlanini, Rome

1105 AZ

Academisch Medisch Centrum at University of Amsterdam, Amsterdam

02-781

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw

08035

Hospital General Universitari Vall d'Hebron, Barcelona

EC1A 7BE

Saint Bartholomew's Hospital, London

G11 6NT

Western Infirmary, Glasgow

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00085228 - Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate | Biotech Hunter | Biotech Hunter